INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion

👍👍

Ließt sich gut ✌️

https://www.prnewswire.com/news-releases/intellia-and-regeneron-announce-landmark-clinical-data-showing-deep-reduction-in-disease-causing-protein-after-single-infusion-of-ntla-2001-an-investigational-crispr-therapy-for-transthyretin-attr-amyloidosis-301320471.html

This Biotech Is Editing Genes Inside the Body. What It Means for the Stock. https://www.barrons.com/articles/this-biotech-is-editing-genes-inside-the-body-what-it-means-for-the-stock-51624562859?mod=hp_LEADSUPP_3 Gene-editing startups have captured the attention—and wallets—of Wall Street. They’re powered by the Nobel Prize-winning technique known as Crispr-Cas9, and an important test of the technology’s value is coming Saturday. Intellia Therapeutics and partner Regeneron Pharmaceuticals will share the world’s first data from a Phase 1 trial of a therapy that edits flawed genes inside the body. The treatment, developed by Intellia with Regeneron’s backing, turns off a mutant gene that drives liver cells to make a harmful protein that damages the heart and nerves. The disease, known as transthyretin amyloidosis, or ATTR, is treatable now only with drugs. Encouraging numbers from the Phase 1 trial would vindicate the investors who bid up Intellia stock (ticker: NTLA) some 275% in the past year. By comparison, the Nasdaq Composite rose about 40% and Regeneron (REGN) lost 17% as excitement about its Covid-19 antibody products waned. ... “This will be a big catalyst for the whole field of gene editing,” said Luca Issi, an analyst at RBC Capital Markets who is betting the data will be positive. He launched coverage of Intellia in May with an Outperform rating. Issi prefers Intellia over peers Crispr Therapeutics (CRSP) and Editas Medicine (EDIT) because of its lead in editing genes inside the body. Editas actually launched the first clinical trial of an in-body technique, but is targeting a rare eye disorder in its first clinical trial and won’t report its data until later this year. Crispr Therapeutics has treated more patients in its clinical trials than both Intellia and Editas, but those therapies— for cancer and sickle-cell disease—are performed outside the body: A patient’s cells are harvested, edited in a lab, then reinfused. For Issi, Intellia needs to deliver results that show its therapy is safe and at least 80% effective in cutting the harmful protein. If the rate is that high, he thinks the treatment will be judged a worthy alternative to current drugs. Infusions of Alnylam products can reduce the harmful protein by over 80%. Pfizer’s pills render some of the protein harmless, slowing the damage done by the disease. If Intellia delivers an impressive number, Issa thinks the stock could jump 50% from recent levels around $85. A successful one-time treatment could be priced above $1 million, Issa believes, with annual sales surpassing $2 billion a decade from now. If investors come around to his way of thinking, the analyst sees Intellia stock worth $110 within a year. Guggenheim’s Debjit Chattopadhyay also thinks Intellia has to match or top Alnylam’s 80% to pose a real challenge. ...

https://www.globenewswire.com/news-release/2021/06/24/2252489/0/en/Intellia-Therapeutics-Names-James-Basta-J-D-as-Executive-Vice-President-General-Counsel-and-Corporate-Secretary.html Intellia Therapeutics ernennt James Basta, JD, zum Executive Vice President, General Counsel und Corporate Secretary

Blackstone Life Sciences, Cellex Cell Professionals und Intellia Therapeutics gründen neues CAR-T-Zell-Unternehmen https://www.presseportal.de/pm/139361/4949104

Intellia Therapeutics (NTLA) Amends License and Collaborative Research Agreement with Novartis (NVS), To Make $10M Payment https://www.streetinsider.com/dr/news.php?id=18574773&gfv=1

Intellia and Sangamo preferred as RBC extends gene editing coverage https://seekingalpha.com/news/3690383-intellia-and-sangamo-preferred-as-rbc-extends-gene-editing-coverage ... The analysts Luca Issi and Lisa Walter have issued outperform ratings on Intellia Therapeutics (NTLA -2.9%) and Sangamo Therapeutics (SGMO -2.2%). And Editas Medicine (EDIT -3.5%) and Beam Therapeutics (BEAM -3.7%) were both rated sector perform. Given the ‘broadest/ deepest gene-editing toolbox in the space,’ Intellia is poised to close the valuation gap with CRISPR, the analysts argue giving the stock a price target of $110.00 per share to indicate ~49.1% upside to the last close. Intellia’s Phase 1 study of NTLA-2001 for transthyretin amyloidosis ("ATTR") is expected to yield topline data in 2021 which according to analysts is a major data readout with implications across the space. ...

👍 Gerne (wenn ich was finde)

Liest sich super😉👌🏻. Thx Summer.76 für deine Links🤘🏻

Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis https://www.globenewswire.com/news-release/2021/03/30/2201454/0/en/Intellia-Therapeutics-Investigational-CRISPR-Treatment-NTLA-2001-Receives-European-Union-Orphan-Drug-Designation-for-ATTR-Amyloidosis.html

https://angioedemanews.com/2021/03/22/intellia-seeks-to-advance-its-gene-editing-therapy-to-human-trials/

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium https://www.globenewswire.com/news-release/2021/03/10/2190315/0/en/Intellia-Therapeutics-Presents-Preclinical-Proof-of-Concept-for-CRISPR-based-In-Vivo-Editing-of-Bone-Marrow-at-Keystone-eSymposium.html

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results https://www.globenewswire.com/news-release/2021/02/25/2182349/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html • Expects to report initial data from Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR), in 2021 • On track to submit an IND or IND-equivalent in mid-2021 for NTLA-5001 for the treatment of acute myeloid leukemia (AML) • Intends to submit an IND or IND-equivalent in 2H 2021 for NTLA-2002 for the treatment of hereditary angioedema (HAE) • Plans to nominate at least one new development candidate in 2021 from broad research efforts and continued platform innovation • Ended 2020 with strong cash position of $597.4 million       ...

Ist der Hype vorbei??

Na dann freu dich das du nun 60€ Wert hast ;)